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immunohistochemical and gene expression 
evaluation. Blood was collected for the 
determination of several serum proliferative 
and inflammatory markers. Lipid 
peroxidation, through serum 
malondialdehyde (MDA) content, and total 
antioxidant status (TAS) were also evaluated.
 
RESULTS
 
Sirolimus caused a marked inhibition of 
bladder tumour growth. When compared 
with group 3, group 4 had a reduced 
proportion of rats with tumour (three of 
eight vs eight of 12), and significantly fewer 
tumours per rat, with a mean (
 
SD
 
) of 
1.00 (0.0) vs 1.88 (0.35), and tumour volume 
per tumour, of 0.30 (0.11) vs 66.1 (48.9) mm
 
3
 
, 
with less aggressive histological changes, i.e. 
a marked reduction in hyperplasia (four of 
eight vs 12/12), high-grade dysplasia (four of 
eight vs 11/12) and urothelial tumour. Rats in 
group 4 had no infiltrative bladder cancers 
and had a lower incidence of high-grade 
tumours than rats in group 3. The rats in 
group 4 had decreased serum levels of 
transforming growth factor-
 
β
 
1, higher 
levels of tumour necrosis factor-
 
α
 
, and 
higher levels of serum TAS and a better 
serum MDA/TAS ratio, a marker of more 
favourable redox status. Furthermore, the 
down-regulation of bladder caspase 3 gene 
expression and the increased Ki67 
immunostaining in group 3 were 
significantly attenuated in group 4.
 
CONCLUSIONS
 
Sirolimus given as an oral agent, 2 mg/kg/
day, significantly inhibited rat bladder 
carcinogenesis. Sirolimus reduced the 
number and volume of tumours and induced 
a less aggressive histological behaviour. This 
might be due to antiproliferative and 
antioxidant properties, as well as to the 
restoration of apoptotic pathways.
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OBJECTIVE
 
To investigate the anticarcinogenic effects of 
sirolimus 2 mg/kg/day on a rat model of 
urinary bladder carcinogenesis induced with 
N-butyl-N(4-hydroxybutyl)nitrosamine 
(BBN).
 
MATERIALS AND METHODS
 
Thirty-six male Wistar rats were divided into 
four groups: 1, a control group (eight), given 
tap water only; 2, a sirolimus control group 
(eight), given 2 mg/kg/day; 3, a carcinogen 
(BBN) group (12) exposed to 0.05% BBN; 4, a 
treatment group (sirolimus/BBN; eight) 
given 2 mg/kg/day 
 
+
 
 0.05% BBN. In the 
tumour-induction phase, from week 1 to 
week 8, rats from groups 3 and 4 received 
BBN 
 
ad libitum
 
 in drinking water. In the 
treatment phase, from week 8 to week 20, 
rats from groups 2 and 4 received sirolimus 
2 mg/kg/day by an oesophageal cannula. At 
week 20 the rats were killed humanely, and 
the number and size of tumours recorded. 
The bladders were collected for histological, 
 
INTRODUCTION
 
Bladder cancer is a very prevalent tumour, 
accounting for 5–10% of all malignancies in 
Western countries [1]. Despite adequate 
treatment and follow-up, 30–80% of these 
patients develop recurrent tumours within 5 
years, and up to 45% can progress to more 
invasive and aggressive forms of cancer [2]. 
The burden of bladder cancer could be 
reduced through the implementation of 
several primary and secondary prevention 
strategies, including the elimination of known 
risk factors. Furthermore, this cancer can be a 
good model for pharmacological prevention. 
Chemopreventive properties of several agents 
have been studied, such as green-tea 
polyphenols, soy products, vitamins, selenium 
and NSAIDs [3]. However, an efficient agent 
that could easily be given to high-risk patients 
has not been found.
Sirolimus is a natural macrocyclic lactone 
produced by 
 
Streptomyces hygroscopicus
 
, 
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which was discovered in the soil of the Vai 
Atari region of Rapa Nui (Easter Island, 1975) 
[4]. It is a potent immunosupressor widely 
used to prevent allograft rejection in organ 
transplantation. It binds intracellularly to the 
immunophilin FKBP-12, forming a complex 
that inhibits the enzymatic activation of the 
mammalian target of rapamycin (mTOR) [5]. 
mTOR is a member of a family of protein 
kinases termed phosphoinositide 3-kinase 
related kinases, which are involved in many 
critical regulatory cellular functions such as 
cell-cycle progression, cellular responses 
to DNA damage, DNA repair and DNA 
recombination [6]. Thus, sirolimus has potent 
antiproliferative properties due to its ability to 
modulate critical signal-transduction 
pathways that link mitogenic stimuli to the 
synthesis of proteins required for cell-cycle 
progression [7]. Sirolimus has shown 
promising antitumoral activity in several 
cancers but it has not previously been used in 
bladder cancer [8–11].
 
MATERIALS AND METHODS
 
Thirty-six male Wistar rats (Charles River 
Laboratory Inc, Barcelona, Spain), 250–285 g, 
8 weeks old, were maintained in an air-
conditioned room, subjected to 12-h dark/
light cycles and given standard laboratory rat 
chow (IPM-R20, Letica, Barcelona, Spain) and 
free access to tap water. Animal experiments 
were conducted according to the European 
Communities Council Directives on Animal 
Care.
The rats were divided in four groups: 1, a 
control group of eight given tap water only; 2, 
a sirolimus control group of eight given 2 mg/
kg/day (Rapamune®, Wyett Europe Ltd, 
Berkshire, UK); 3, a carcinogen group of 12, 
given 0.05% 
 
N
 
-butyl-
 
N
 
-(4-hydroxybutyl) 
nitrosamine (BBN; Tokyo Chemical Industry 
Co., Ltd, Tokyo, Japan); and 4, a treatment 
group of eight, given 2 mg/kg/day sirolimus 
and 0.05% BBN.
The experimental study was conducted in two 
steps, a tumour-induction phase from week 1 
to week 8, when rats from groups 3 and 4 
received BBN 
 
ad libitum
 
 in drinking water, and 
a treatment phase from week 8 to week 20, 
when rats in groups 2 and 4 received 
sirolimus 2 mg/kg/day by an oesophageal 
cannula. All rats completed the 20-week 
study protocol, and body weight and amount 
drunk were monitored during the 
experimental period.
At the end of treatment the rats were injected 
with intraperitoneal anaesthesia, 2 mg/kg of a 
2 : 1 (v : v) 50 mg/mL ketamine (Ketalar®, 
Parke-Davis, Pfizer Laboratories Lda, Seixal, 
Portugal) solution in 2.5% chlorpromazine 
(Largatil®, Rhône-Poulenc Rorer, Vitória 
Laboratories, Amadora, Portugal). Blood 
samples were immediately collected by 
venepuncture from the jugular vein in needles 
with no anticoagulant (for serum samples 
collection) or with EDTA.
Under anaesthesia the rats were killed by 
cervical dislocation, and the lungs, stomach, 
liver, kidneys and intestines immediately 
removed, weighed and placed in ice-cold 
Krebs buffer or formaldehyde for further 
analysis. Before removal, bladders were 
intraluminally injected with a buffered 
formaldehyde solution as pre-fixation for 
histological analyses. A ligature was placed 
around the bladder neck to maintain proper 
distension.
For a macroscopic quantitative analysis 
(number and volume of tumours), each 
bladder pre-fixed in formaldehyde was 
carefully opened, the lumen inspected for 
grossly visible lesions and the number of 
tumours per rat and the volume of each 
tumour were recorded to calculate the 
incidence of tumour per group and the mean 
volume per rat. A tumour was defined as a 
lesion of 
 
>
 
0.5 mm in diameter.
For the microscopic qualitative analysis 
(bladder histology), the bladder was 
immersion-fixed in 4% buffered 
formaldehyde and processed for paraffin 
sectioning. Three slices from each bladder 
were embedded, 3 
 
μ
 
m sections cut and 
stained with haematoxylin and eosin (H&E), 
and examined histologically by one author 
(M.F.X.C.) unaware of the treatments.
For bladder Ki67 immunostaining, formalin-
fixed, paraffin-embedded tissue blocks 
were sectioned at 5-mm thickness, and 
immunostained using the avidin-biotin 
peroxidase method, as previously described 
[12]. Sections were deparaffinized in xylene 
and rehydrated through graded alcohols. 
Endogenous peroxidase activity was blocked 
by 3% hydrogen peroxide in PBS, the slides 
washed three times (2 min each) and then 
incubated with blocking serum for 10 min to 
block nonspecific binding. The excess of 
blocking serum was removed, and the 
sections than incubated with primary 
antibody (anti-Ki67 monoclonal antibody; 
NeoMarkers, LabVision, Fremont, CA, USA) 
diluted at 1 : 200) for 30 min at room 
temperature. After washing, the biotinylated 
secondary antibody was used as a second 
layer for 10 min. The sections were then 
washed three times for 5 min each. 
Streptavidin-peroxidase complex was applied 
for 10 min, the sections washed in PBS, and 
the peroxidase signal was developed in 0.05% 
diaminobenzidine and 0.01% hydrogen 
peroxide in PBS. The sections were lightly 
counterstained with haematoxylin. Brown 
diffuse nuclear staining was seen in positive 
cases of Ki67.
For bladder gene expression analysis, total 
RNA was isolated from paraffin-embedded 
bladder tissue sections. Samples were 
processed according to the protocol of 
Purification of Total RNA from FFPE Tissue 
Sections from RNeasy® FFPE kit (Qiagen, 
Hilden, Germany). Total RNA was eluted in 
30 
 
μ
 
L of RNase-free water (without optional 
treatment with DNAse). To quantify the 
amount of total RNA extracted and verify RNA 
integrity (using the RNA integrity number), 
samples were analysed using 6000 Nano 
Chip® kit, in Agilent 2100 bioanalyser 
(Agilent Technologies, Walbronn, Germany) 
and 2100 expert software, following the 
manufacturer’s instructions. The yield from 
isolation was from 0.5 to 3 
 
μ
 
g; RNA integrity 
numbers were 6.0–9.0 and purity (A
 
260
 
/A
 
280
 
) 
was 1.8–2.0.
RNA was reverse transcribed with 
SuperScript
 
TM
 
 III First-Strand Synthesis 
System for RT-PCR (Invitrogen, CA, USA); 1 
 
μ
 
g 
of total RNA was mixed with a 2
 
×
 
 First-Strand 
Reaction Mix and a SuperScript
 
TM
 
 III Enzyme 
Mix (oligo(dT) plus random hexamers), 
according to the manufacturer’s instructions. 
Reactions were carried out in a thermocycler 
Gene Amp PCR System 9600 (Perkin Elmer, 
Norwalk, CO, USA), for 10 min at 25 
 
°
 
C, 
50 min at 50 
 
°
 
C and 5 min at 85 
 
°
 
C. Reaction 
products were then digested with 1 
 
μ
 
L RNase 
H for 20 min at 37 
 
°
 
C and, finally, cDNA eluted 
to a final volume of 50 
 
μ
 
L and stored at 
 
−
 
20 
 
°
 
C.
Relative gene expression was quantified 
by real-time PCR using the LightCycler® 
480 II (Roche, Rotkreuz, Switzerland). A 
normalization step preceded the 
quantification of gene expression, using 
geNorm Housekeeping Gene Selection 
kit for 
 
Rattus norvegicus
 
 (Primer Design, 
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Southampton, UK) and geNorm software 
(Ghent University Hospital, Center for Medical 
Genetics, Ghent, Belgium) to select optimal 
reference genes for the present study [13]; 
the selected genes were glyceraldehyde 
phosphate dehydrogenase (Gapdh) and 
ribosomal protein L13 (Rpl13).
Real-time PCR reactions used QuantiTect® 
Primer Assay (Qiagen, Hilden, Germany) for 
the gene of interest, caspase 3, and the 
endogenous controls selected previously 
(Table 1), together with QuantiTect SYBR 
Green PCR Kit Gene expression. RT-PCR 
reactions were carried out with 100 ng cDNA 
sample, primers (50–200 n
 
M
 
) and 1
 
×
 
 
QuantiTect SYBR Green PCR Master Mix. Non-
template control reactions were used for each 
gene, to ensure no unspecific amplification. 
Reactions were performed with the following 
thermal profile: 10 min at 95 
 
°
 
C plus 40 cycles 
of 15 s at 95 
 
°
 
C and 1 min at 60 
 
°
 
C. Real-time 
PCR results were analysed with LightCycler 
480 software, version 1.5 (Roche, Rotkreuz, 
Switzerland) and quantification used the 2
 
–
 
ΔΔ
 
Ct
 
 method [14].
Serum levels of TGF-
 
β
 
1, TNF-
 
α
 
 and 
interleukin-1
 
β
 
 (IL-1
 
β
 
) were measured using 
ultrasensitive Quantikine® ELISA kits (R & D 
Systems, Minneapolis, USA). Serum C-reactive 
protein (CRP) was determined using an ELISA 
kit from Helica Biosystems, Inc. (Fullerton, 
CA, USA). All assays were performed in 
duplicate.
Serum redox status was assessed by two 
methods: a thiobarbituric acid reactive-
species assay, in which serum was used to 
determine the products of lipid peroxidation, 
i.e. malondialdehyde (MDA), as previously 
described [15]; and a ferric reducing 
antioxidant potential (FRAP) assay, in which 
serum antioxidant capacity was measured as 
FRAP, as previously described [16], and termed 
the total antioxidant status (TAS).
Serum creatinine, serum aspartate 
aminotransferase (AST) and alanine 
aminotransferase (ALT) levels were assessed 
using validated automatic methods and 
equipment (Hitachi 717 analyser, Roche 
Diagnostics Inc., MA, USA). Serum total 
cholesterol (total-c), high-density lipoprotein 
cholesterol (HDL-c), low-density lipoprotein 
cholesterol (LDL-c) and triglycerides (TGs) 
were also analysed on the Hitachi 717 
analyser using standard laboratory methods. 
Plasma glucose levels were measured using a 
glucose oxidase commercial kit (Sigma, St. 
Louis, MO, USA).
Several haematological variables were 
measured in EDTA-whole blood using an 
automatic Coulter Counter® (Beckman 
Coulter Inc., Foster City, CA, USA), i.e. a red 
blood cell (RBC) count, haematocrit, 
haemoglobin concentration, platelet and 
white blood cells (WBC) count.
The results are presented as the mean (
 
SEM
 
) 
and groups compared using a one-way 
 
ANOVA
 
 
and Fisher’s test, with significance indicated 
at 
 
P
 
 
 
<
 
 0.05.
 
RESULTS
 
All rats completed the 20 week protocol; the 
mean intake of food and fluids was not 
significantly different among the four groups. 
In the experimental study, sirolimus caused a 
marked inhibition of bladder tumour growth 
(Table 2). When compared with group 3, the 
mean number of tumours per rat, of 
0.38 (0.18) vs 1.25 (0.35) and the mean 
number of tumours per rat with tumour, of 
1.00 (0.0) vs 1.88 (0.35), were significantly 
lower in group 4. There was also a much lower 
tumour volume per tumour, of 0.30 (0.11) vs 
66.1 (48.9) mm
 
3
 
 (
 
P
 
 
 
<
 
 0.05) and fewer rats with 
tumour (three of eight vs eight of 12) in group 
4, although in this case the difference was not 
statistically significant. On gross inspection 
the bladder walls of rats in group 3 were 
thicker, more irregular, and with more blood 
vessels (Fig. 1).
Histological examination (Fig. 2) confirmed 
the less aggressive histological changes in 
group 4 than in the group 3, with a marked 
reduction in hyperplasia (four of eight vs 
12/12), high-grade dysplasia (four of eight vs 
11/12) and urothelial tumour (Table 2). Rats in 
group 4 showed no infiltrative bladder 
cancers and had a lower incidence of high-
grade tumours than those in group 3 
(Table 2). No bladder from control groups 1 
and 2 showed macroscopic or histological 
signs of tumour, with normal wall texture, 
thickness and vascularization (Figs 1,2).
Rats in group 4 had lower serum levels of 
TGF-
 
β
 
1 (
 
P
 
 
 
<
 
 0.05) but significantly higher 
levels of TNF-
 
α
 
 (
 
P
 
 
 
<
 
 0.01) than those in group 
3 (Fig. 3). There were no differences in the 
inflammatory markers CRP and IL-1
 
β
 
. When 
compared with group 3, rats in group 4 
also had a better TAS, of 572.6 (13.2) vs 
523.5 (17.3) 
 
μ
 
mol/mL (
 
P
 
 
 
<
 
 0.05), with less 
oxidative aggression, as shown by the lower 
values of serum MDA, of 0.413 (0.056) vs 
0.465 (0.033) 
 
μ
 
mol/mL, and a better serum 
MDA/TAS ratio of 0.58 (0.04) vs 0.93 (0.04) 
 
×
 
 
10
 
–3
 
 (
 
P
 
 
 
<
 
 0.001), a marker of more favourable 
redox status.
The increase in bladder Ki67 immunostaining 
in group 3 was clearly attenuated in group 4 
(Fig. 4). Real time-PCR gene expression of 
caspase 3 showed that BBN caused a 
decreased expression in the bladder tissue and 
this reduction was significantly attenuated 
when the drug was used concomitantly in 
group 4 (Fig. 5).
The lipid profile showed that sirolimus 
caused hypercholesterolaemia and 
hypertriglyceridaemia in both the control 
 
TABLE 1 
 
Genes of interest and reference genes used in the present real-time quantitative PCR study
 
Symbol Gene name GenBank ID Primer pair origin
Amplicon
length, bp
Casp3 Caspase 3 NM 012922
 
Rattus norvegicus
 
 QuantiTect® Primer Assay
QT01794429(Qiagen, Hilden, Germany)
115
Gapdh Glyceraldehyde phosphate
dehydrogenase
NM 017008
 
Rattus norvegicus
 
 geNorm Housekeeping Gene
Selection kit(PrimerDesign, Southampton, UK)
87
Rpl13 Ribosomal proteinL13 NM000977 77
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TABLE 2 
 
Results for the macroscopic and histological findings
 
Mean (
 
SEM
 
) or n variable
Group
1, control
2, SIR 
control
3, BBN 4, sirolimus/BBN
Overall Tumour Overall Tumour
Macroscopic
% of tumours/group 0 0 8/12 3/8
Total no. of tumours 0 0 15 3
No. of tumours/rat 0 0 1.25 (0.35) 1.88 (0.35) 0.38 (0.18)* 1.00 (0.0)†
Tumour volume, mm
 
3
 
Per rat with tumour 0 0 124.0 (90.4) 0.30 (0.11)
Per tumour 0 0 66.1 (48.9) 0.30 (0.11)
Microscopy (histology)
Pre-neoplastic lesions, %
Hyperplasia 0 0 12/12 8/8 4/8* 2/3
High-grade dysplasia 0 0 11/12 8/8 4/8* 3/3
Urothelial tumour 0 0 8/12 3/8
Malignant lesions
Papillary 0 0 12/15 3/3
Infiltrative 0 0 3/15 0/0
Tumour grade
Low (G1) 0 0 7/15 2/3
High (G2/G3) 0 0 8/15 1/3
 
*
 
P
 
 
 
<
 
 0.05, †
 
P
 
 
 
<
 
 0.01 vs group 3.
 
FIG. 1. 
 
Macroscopic evaluation at the end of the 20 week-protocol: Bladders from control group 1 (
 
A
 
) and control group 2 (
 
B
 
) showed no macroscopic signs of tumour. 
Rats from group 3 had larger bladder tumours with increased vascularization (
 
C,D
 
), in clear contrast with rats from group 4 (
 
E,F
 
).
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group 2 and group 4. Rats in these two groups 
also had changes in hepatic function, with 
elevated AST and a slightly higher creatinine 
value. No signs of mielotoxicity were 
detected. Rats receiving sirolimus had a lower 
weight at the end of the protocol (Table 3). 
The lungs, liver, stomach and intestines were 
normal on gross inspection, and on 
histological examination there were no signs 
of metastasis.
 
DISCUSSION
 
Bladder cancer is the fourth most common 
tumour in men and the eighth in women. It 
has a high prevalence, a poor prognosis if 
diagnosed late or treated inadequately, and a 
high socio-economic cost [1]. Bladder 
tumours are associated with exogenous risk 
factors, including cigarette smoking and 
occupational carcinogens, e.g. aromatic 
amines and polycyclic aromatic hydrocarbons 
[17–19]. Other exposures include chronic UTIs, 
cyclophosphamide use and radiotherapy.
The burden of bladder cancer could be 
reduced by implementing several primary 
and secondary prevention strategies. 
Further to the elimination of known risk 
factors, this cancer could also be a good 
model for pharmacological prevention 
studies.
Urothelial TCC is present in 
 
>
 
90% of the 
cases; the malignant transformation is a 
continuous process that includes proliferative 
epithelial abnormalities, preneoplastic 
changes and malignant lesions (carcinoma 
 
in 
 
FIG. 2. 
 
Histological data (H&E, 
 
×
 
 100) showed no tumour in controls (group 1) (
 
A
 
) or group 2 (
 
B
 
). In the group 3, high-grade dysplasia, with carcinoma in situ were more 
frequent (
 
C
 
) and bladder cancers were larger and more invasive (
 
D
 
) than in group 4, who had hyperplasia, low-grade dysplasia (
 
E
 
) and tumours that were more 
superficial, of lower grade and smaller (
 
F
 
).
 
FIG. 3. Serum markers of proliferation and inflammation: aaa, P < 0.001 vs control group; bb, P < 0.01 vs 
group 3.
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situ, papilloma and carcinoma) [1,20,21]. An 
early treatment with drugs that reverse these 
molecular and morphological pathways could 
prevent bladder cancer. Pre-clinical studies 
using green tea polyphenols, soy products, 
vitamins, selenium and NSAIDs showed that 
bladder cancer is responsive to prevention 
strategies [3,22–24]. Our group has 
also shown the efficacy of selective 
cyclooxygenase-2 inhibition for bladder 
cancer chemoprevention in rats [22]. 
However, an efficient agent that could easily 
be given to high-risk patients has not been 
found.
Our experimental bladder carcinogen model in 
rats, induced using BBN 0.05% in drinking 
water over 8 weeks, was used previously, with 
similar tumour induction efficacy [22,24–26]. 
Oral administration of BBN produces bladder 
tumours analogous to those in humans, in a 
dose- and time-dependent manner. At week 8 
the carcinogen was stopped and we started 
pharmacological treatment with sirolimus; to 
our knowledge, sirolimus has not been 
studied in animal models of bladder cancer.
The anticarcinogenic potential of sirolimus 
is due to the blockade of mTOR, which 
regulates essential transduction pathways 
and is involved in the coupling of growth 
stimuli with cell-cycle progression. Growth 
factor-growth factor receptor interactions 
affect the phosphorylation state of mTOR 
[27]. Blocking mTOR affects the function 
of the eukaryotic initiation factor 4E-
binding protein-1 and decreases the 
activity of the 40S ribosomal protein S6 
kinase, leading to arrest in the cell-cycle 
progression from G1 to S [6,28,29], thus 
reducing cell proliferation. Sirolimus 
also prevents cyclin-dependent kinase 
activation, inhibits retinoblastoma protein 
FIG. 4. Immunostaining micrograph of Ki67 expression (the positivity is brown nuclear staining) in group 3 
(BBN, A) and in group 4 (SIR/BBN, B). Avidin-biotin peroxidase method (original × 400).
FIG. 5. Relative bladder gene expression of caspase 3 
for the groups under evaluation. aa, P < 0.01 vs 
control group; bb, P < 0.01 vs group 3 (BBN).
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TABLE 3 Biochemical data and weight for the four groups at the end of the study (week 20)
Mean (SEM) variable
Group
1, control 2, SIR control 3, BBN 4, sirolimus/BBN
Glycaemia, mg/dL 192.14 (10.65) 215 (2.53) 210.77 (7.56) 210 (7.92)
Renal function, creatinine, mg/dL 0.58 (0.02) 0.68 (0.04)* 0.62 (0.02) 0.51 (0.02)¶
Hepatic function
AST, UI/L 51.57 (1.09) 104.25 (8.37)† 78.15 (6.04*) 118.6 (9.32)¶
ALT, UI/L 30.86 (1.75) 81 (3.79)† 38.15 (2.92*) 23.4 (1.66)¶
Lipid profile
Total-c, mg/dL 54.67 (6.29) 126.5 (4.35)† 51.92 (3.40) 57.8 (2.71)
TGs, mg/dL 160.17 (15.98) 316.25 (5.59)† 125.77 (9.04) 194.4 (16.53)¶
HDL-c, mg/dL 31.17 (3.21) 82.4 (4.12)† 35.08 (2.51) 28.4 (1.29)
LDL-c, mg/dL 15.67 (1.86) 14.5 (0.87) 15.15 (1.43) 18.2 (0.66)
Haematological data
RBC count, 109/L 7.58 (0.29) 8.06 (0.13) 8.072 (0.11) 8.86 (0.18)‡
Haematocrit, % 40.42 (1.69) 41.32 (0.68) 42.11 (0.44) 44.5 (0.78)
Haemoglobin, g/dL 14.15 (0.52) 14.6 (0.25) 14.60 (0.15) 15.3 (0.25)
Platelets, ×109/L 990.67 (46.21) 909.8 (26.17) 1008.13 (46.96) 806 (44.48)‡
WBC count, 109/L 4.60 (0.56) 4.96 (0.19) 3.52 (0.26) 5.83 (0.2)‡
Weight, g 560 (8.1) 459 (16.2)* 548.3 (16.2) 493 (14.9)°
*P < 0.05, †P < 0.01 vs control group; °P < 0.05, ‡P < 0.01, ¶P < 0.001 vs group 3.
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phosphorylation and accelerates the 
turnover of cyclin D1.
The impressive antiproliferative activity of 
Sirolimus was reported in several preclinical 
studies, including cell-line cultures of human 
prostate, breast and small cell lung cancers, 
glioblastoma, melanoma and T-cell leukaemia, 
and in clinical studies [6,8–11,28,30]. 
Tensirolimus, another mTOR inhibitor, has 
been approved for clinical use in metastatic 
RCC, reinforcing the putative potential of 
these compounds as antineoplastic agents 
[31].
The mechanisms underlying the 
anticarcinogenic properties of sirolimus 
remain to be fully elucidated, but inhibition of 
cell proliferation appears to be the most 
important. Sirolimus could have a direct 
inhibitory effect on urothelial tumour cell 
proliferation, but also indirectly through 
reduction of endothelial cells and tumour 
angiogenesis. Increased tumour cell 
proliferation is a feature of bladder cancer 
and the disruption of mTOR pathways appears 
to be involved [32,33]. Numerous mutations 
of upstream regulators of mTOR signalling 
can lead to hyperactivation, resulting in 
uncontrolled cell growth [34]. All these 
arguments justified the pioneering use of 
sirolimus in an experimental model of bladder 
carcinogenesis.
In the present study, sirolimus had evident 
antiproliferative activity, causing fewer rats 
with tumour (three of eight vs eight of 12), 
together with significantly fewer tumours per 
rat and an even more impressive decrease in 
the tumour volume, with less aggressive 
histological changes, i.e. high-grade urothelial 
carcinoma; all the bladder tumours were TCC. 
Administration of sirolimus also tended to 
decrease the depth of invasion; tumours in 
group 4 rats were all superficial, while in 
group 3, 20% had deeper invasion, although 
limited to the lamina propria mucosa. In 
agreement with these data, the number and 
severity of pre-neoplastic lesions, hyperplasia 
and high-grade dysplasia were also reduced. 
These data show the ability of sirolimus to 
inhibit bladder tumour growth.
Increased production of TGF-β1 can occur 
in different tumour types and correlates 
with their severity. TGF-β1 can create a 
microenvironment that promotes tumour 
growth, invasion and metastasis [35,36]. In 
the present study, rats in group 4 had lower 
levels of TGF-β1 and the inhibition of this 
signal-transduction pathway could 
potentially explain the decrease in tumour 
growth and aggressiveness by sirolimus. This 
effect was accompanied by reduced Ki67 
bladder immunostaining, a validated marker 
of proliferation, particularly in the bladder 
cancer [12,37], thus reinforcing the 
antiproliferative properties of sirolimus.
TNF-α is a multifunctional cytokine involved 
in apoptosis, cell survival, inflammation and 
immunity. It has a role in regulating the 
apoptosis/proliferation balance in tumour 
cells [38].The reason for the elevated value of 
TNF-α in group 4 is not clear, but it might 
reflect the effect of sirolimus in the life-death 
signalling regulation, causing a reduction of 
bladder tumour burden through activation of 
apoptotic pathways [39]. Caspase-3 is a key 
mediator of the apoptotic pathway. In the 
present study, sirolimus significantly 
attenuated the down-regulation of caspase 3 
gene expression seen in rats in group 3, thus 
showing that the chemopreventive effect of 
sirolimus on bladder cancer growth involves 
mechanisms related to the restoration of the 
caspase 3 apoptosis pathway. Our results are 
in agreement with the role of caspase 3 
reduction in bladder cancer development, and 
a role of caspase 3 activity for cancer 
prevention, as previously reported in other 
studies with other compounds [40–42].
Reactive oxygen species are capable of 
damaging DNA and other biomolecules, thus 
potentially promoting the development of 
malignancy [43]. Sirolimus also had a positive 
effect on redox status, with a higher 
antioxidant capacity, as shown by the higher 
serum TAS and favourable MDA/TAS index, 
contributing to its anticarcinogenic 
properties. There were no differences in the 
markers of inflammation.
In conclusion, in this experimental study, 
sirolimus given as an oral agent at 2 mg/kg/
day significantly inhibited rat bladder 
carcinogenesis, with minor adverse effects. 
Sirolimus reduced the number and volume of 
tumours, and induced less aggressive 
histological behaviour. This might be due to 
antiproliferative and antioxidant properties, 
together with a restoration of the caspase 3 
apoptosis pathway. Although this was a 
preliminary study, the results are promising 
and justify further investigation, including 
other dosages, to validate the role of cancer 
chemoprevention strategies based on the 
therapeutic use of mTOR inhibitors such as 
sirolimus.
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